98%
921
2 minutes
20
The study focused on biomarkers of kidney injury as predictors of mortality in patients with chronic heart failure (CHF) in a long-term follow-up (median 104 months). KIM-1, NAG and NGAL were assessed from urine, NT-proBNP from blood samples. 149 patients (age 62 ± 12 years) with CHF (mean EF 30% [IQR 24-40%]) were enrolled. 79 (53%) patients died. Cox regression analysis revealed Log2NAG (HR: 1.46, CI: 1.12-1.89), Log2KIM-1 (HR: 1.23, CI: 1.02-1.49) and Log2NT-proBNP (HR: 1.50, CI: 1.32-1.72) as significant predictors of all-cause mortality as opposed to Log2NGAL (HR: 1.04, CI: 0.90-1.20). Log2NAG remained a significant predictor of all-cause mortality in a multivariate Cox regression model but lost its predictive value in combination with Log2NT-proBNP. The 10-year follow-up suggests NAG as a predictive tubular marker in CHF patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/bmm-2020-0366 | DOI Listing |
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFDiabetes Metab Syndr Obes
September 2025
Department of Primary Health, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Kigali, Republic of Rwanda.
Background: While psychological stress cannot be dissociated from chronic diseases, the extent to which it impacts the management of chronic diseases is poorly understood. This cross-sectional study investigated the prevalence and impact of psychological stress among Rwandan patients with chronic diseases, particularly hypertension, heart failure, malignancies, diabetes, and kidney failure.
Methods: This cross-sectional study was conducted among internal medicine patients receiving treatment for chronic diseases at the University Teaching Hospital of Kigali (n = 81) and the University Teaching Hospital of Butare (CHUB) (n = 78) between May 1 and June 30, 2024.
Eur Heart J Case Rep
September 2025
Department of Cardiology, Toyohashi Heart Center, 21-1 Gobutori, Oyamacho, Toyohashi 441-8530, Japan.
Background: Mitral regurgitation (MR) may rarely worsen after transcatheter aortic valve implantation (TAVI) due to mechanical interference from the transcatheter heart valve (THV). Standard surgical approaches in these cases are often challenging due to anatomical constraints. Thus, there is a need for the development of effective alternatives to address this issue.
View Article and Find Full Text PDFAm Heart J Plus
October 2025
Department of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Introduction: Cigarette smoking is a well-recognized independent risk factor for numerous cardiovascular disorders and contributes to the increasing morbidity and mortality associated with chronic heart diseases (CHD). This study aimed to evaluate how cigarette smoking affects lipid metabolism and inflammatory processes, along with other related mechanisms, in order to better understand the potential cardiovascular risks faced by smokers.
Objectives: To evaluate and compare the serum lipid profile and high-sensitivity C-reactive protein levels between cigarette smokers and non-smokers.
Clin Kidney J
September 2025
Department of Nephrology. University Clinical Hospital, INCLIVA, Valencia. RICORS Renal Instituto de salud Carlos III, Valencia. Spain.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major contributor to systemic metabolic dysfunction and is increasingly recognized as a risk enhancer for both cardiovascular disease (CVD) and chronic kidney disease (CKD). This review explores the complex interconnections between MASLD, CVD, and CKD, with emphasis on shared pathophysiological mechanisms and the clinical implications for risk assessment and management. We describe the crosstalk among the liver, heart, and kidneys, focusing on insulin resistance, chronic inflammation, and progressive fibrosis as key mediators.
View Article and Find Full Text PDF